Tag: percutaneous coronary intervention

1 Month of DAPT Inadequate After Recent ACS

One month of dual antiplatelet therapy (DAPT) followed by 11 months of clopidogrel monotherapy failed to prove noninferiority to 12 unbroken months of DAPT for...

1 Month DAPT Enough After High-Bleeding-Risk PCI

Another trial has added to the movement towards shortening the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). In the MASTER DAPT...

Same-Day Discharge for Elective PCI Safe in Real-World Analysis

Based on a large registry, there appears to be no adverse consequences for same-day discharge following an elective percutaneous cardiovascular intervention (PCI), according to an...

CLARIFY Confirms Meds, Watchful Waiting in Angina, Stable CAD

Further evidence supporting conservative management for most patients with stable coronary artery disease (CAD) and angina comes from a new study of more than 30,000...

‘Thinner Strut’ Bioresorbable Scaffold Holds Own vs Mainstay DES

It was back to the drawing board for bioresorbable vascular scaffolds (BVS), to some degree, after the initially promising ABSORB series of trials dampened any...

Genotype-Guided Antiplatelet Therapy Misses Mark

The observational extended study of the previously reported 12-month randomized TAILOR-PCI trial shows genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI) did not significantly reduce...

Transradial Complex PCI Effective With Slim, Large-Bore Sheath

Transradial vascular access is often preferred over the transfemoral route in percutaneous coronary intervention (PCI) for its lower associated risks of bleeding and vascular complications....

Provisional Second Stent Shows Mettle in LM Bifurcations: EBC MAIN

Another randomized trial has compared two common approaches to stenting complex and challenging left-main (LM) coronary bifurcation lesions, and this one showed little difference between...

Switching From Ticagrelor to Clopidogrel Safe Post-PCI

New support for replacing higher-potency ticagrelor (Brilinta) with clopidogrel as part of dual-antiplatelet therapy (DAPT) 30 days after stenting for acute myocardial infarction comes from...

Arthritis Drug May Curb Myocardial Damage in Acute STEMI

Early use of tocilizumab (Actemra) does not reduce myocardial infarct size but modestly increases myocardial salvage in patients with acute ST-segment elevation myocardial infarction (STEMI),...

Parity Whether Anticoagulation Is Halted or Not for Unplanned Cath

Maintaining oral anticoagulation (OAC) throughout an unplanned cardiac catheterization confers no extra risk and might hold some advantages over periprocedural OAC interruption in patients on...

Delirium Common, Costly After Mitral, Tricuspid Valve Repair

Delirium occurred in nearly 1-in-10 elderly patients after percutaneous mitral and tricuspid valve repair and signaled longer hospital stays and worse survival, a new study...

Radial-to-Backup Artery Switch Adds Limited Risk in ACS PCI

There’s a price to pay for a failed radial artery attempt in invasively managed patients with acute coronary syndrome (ACS), but it may not be...

Ticking All the Right Boxes for Same-Day Discharge PCI

The American College of Cardiology has released a new expert consensus decision pathway to provide practical guidance on same-day discharge after percutaneous coronary intervention (PCI)....

Physician-Level PCI Mortality Data May Be Misleading

Publicly reported percutaneous coronary intervention (PCI) mortality data may be misleading with regard to cardiologists who perform PCI at multiple centers, new research suggests. Dr...

Renowned Interventional Cardiologist Dies of COVID-19

The interventional cardiology community is mourning the loss of Prof Anthony “Tony” Gershlick, MBBS, who died November 20 of COVID-19. He was 69. Gershlick was...

Clopidogrel Bests Ticagrelor for Elective PCI

Ticagrelor failed to unseat clopidogrel as the guideline-recommended P2Y12 inhibitor of choice in patients undergoing elective percutaneous coronary intervention for stable CAD in the randomized...

The ‘Grubby’ Affair of the EXCEL Trial and the European Guidelines

“I disapprove of what you say, but I will defend to the death your right to say it.” The choice of the secretary general of...

Advisory Panel Balks at Neovasc Reducer for Refractory Angina

More than 10 hours of testimony and debate failed to convince a US Food and Drug Administration (FDA) expert advisory panel that existing evidence reasonably...

Optimal Post-PCI FFR Often Missed

Optimization of fractional flow reserve (FFR) after angiographically successful percutaneous coronary intervention (PCI) did not impact clinical outcomes but significantly reduced the proportion of patients...

More Support for Shorter DAPT in High Bleeding Risk PCI

Select high bleeding risk (HBR) patients can safely receive just 1 or 3 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) without...

Tightly iFR-Optimized PCI May Cut Cardiac Event Risk

As much as intracoronary physiologic measures can help operators identify potential ischemia-producing targets for percutaneous coronary intervention (PCI), they may also verify whether the procedure...

Study Questions Routine Long-term Beta-Blocker Post MI

Current American and European guidelines recommending long-term beta-blocker therapy following an acute MI appear to be obsolete in the modern reperfusion era, suggests an analysis...

Early Evolocumab Quickly Lowers LDL After Primary PCI

Early administration of evolocumab significantly reduced levels of LDL cholesterol in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention, according to data...

Trimetazidine Fizzles for Post-PCI Angina

Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a non–ST-elevated myocardial infarction (MI),...